Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mahmoud H. Teaima, Adi Al-Nuseirat, Dalia Abouhussein, Osama A. Badary & Mohamed A. El-Nabarawi. (2021) Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt—case study. Journal of Pharmaceutical Policy and Practice 14:1.
Read now
Read now
Sarah E. Van Pilsum Rasmussen, Shanti Seaman, Diane Brown, Niraj Desai, Mark Sulkowski, Dorry L. Segev, Christine M. Durand & Jeremy Sugarman. (2020) Patient’s Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. AJOB Empirical Bioethics 11:1, pages 40-52.
Read now
Read now
Kohei Kaneko & Tsutomu Ishihara. (2017) Development of liver-specific ribavirin-loaded nanoparticles with reduced cytotoxicity. Cogent Medicine 4:1.
Read now
Read now
Articles from other publishers (66)
Bernadette Lettner, Kate Mason, Zoë R. Greenwald, Jennifer Broad, Erin Mandel, Jordan J. Feld & Jeff Powis. (2023) Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study. The Lancet Regional Health - Americas 22, pages 100490.
Crossref
Crossref
Giuseppina Lo Moro, Giacomo Scaioli, Lorenzo Vola, Laura Guastavigna, Roberta Frattin, Elisabetta De Vito, Fabrizio Bert & Roberta Siliquini. (2023) Exploring Knowledge and Awareness of HCV Infection and Screening Test: A Cross-Sectional Survey Among an Italian Sample. Journal of Community Health.
Crossref
Crossref
William W. L. Wong, Josephine Wong, Karen E. Bremner, Yasmin Saeed, Kate Mason, Arcturus Phoon, Valérie Martel‐Laferrière, Julie Bruneau, Jordan J. Feld, Zeny Feng, Elizabeth Baguley, Samuel S. Lee, Jeff Powis & Murray D. Krahn. (2023) Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings. Liver International 43:4, pages 805-818.
Crossref
Crossref
Gayatri Marathe, Erica E M Moodie, Marie-Josée Brouillette, Charlotte Lanièce Delaunay, Joseph Cox, Valérie Martel-Laferrière, John Gill, Curtis Cooper, Neora Pick, Marie-Louise Vachon, Sharon Walmsley, Marina B Klein, Lisa Barrett, Jeff Cohen, Brian Conway, Curtis Cooper, Pierre Côté, Joseph Cox, M John Gill, Shariq Haider, David Haase, Mark Hull, Valérie Martel-Laferrière, Julio Montaner, Erica E M Moodie, Neora Pick, Danielle Rouleau, Aida Sadr, Steve Sanche, Roger Sandre, Mark Tyndall, Marie-Louise Vachon, Sharon Walmsley & Alexander Wong. (2023) Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada. Clinical Infectious Diseases 76:3, pages e702-e709.
Crossref
Crossref
Fauzia Mahanaz Shorobi, Fatema Yasmin Nisa, Srabonti Saha, Muhammad Abid Hasan Chowdhury, Mayuna Srisuphanunt, Kazi Helal Hossain & Md. Atiar Rahman. (2023) Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions. Molecules 28:3, pages 938.
Crossref
Crossref
Julia Kind, Bettina Maeschli & Philip Bruggmann. (2022) How to set the agenda for hepatitis C: a theory-driven policy analysis. Health Research Policy and Systems 20:1.
Crossref
Crossref
Shelley N. Facente, Rachel Grinstein, Janessa Broussard, Jessica Shost, Soraya Azari, Jennifer Siruno, Jose A. Jimenez, Anne F. Luetkemeyer & Katie Burk. (2022) Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action. Public Health Reports 137:4, pages 649-654.
Crossref
Crossref
Hongwei Wang, Yixin Fang, Weili He, Ruizhe Chen & Su Chen. (2022) Clinical Trials with External Control: Beyond Propensity Score Matching. Statistics in Biosciences 14:2, pages 304-317.
Crossref
Crossref
Shelley N. Facente, Rachel Grinstein, Roberta Bruhn, Zhanna Kaidarova, Erin Wilson, Jennifer Hecht, Katie Burk, Eduard Grebe & Meghan D. Morris. (2022) Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019. PLOS ONE 17:5, pages e0267902.
Crossref
Crossref
Quinnette B. Jones, Kristi Giemza, Lorraine Anglin & Sarah Cottingham. (2022) Treating Hepatitis C in a Substance Use Recovery Program: A Limited-Resource Group Model. NEJM Catalyst 3:5.
Crossref
Crossref
Salma Adnane, Chaimaa Mahad, Sofia Haitami & Ihsane Ben Yahya. (2022) Hepatitis C virus infection and oral lichen planus: A controversial association. Advances in Oral and Maxillofacial Surgery 6, pages 100271.
Crossref
Crossref
Victoria Green & Marina Roytman. (2022) Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review. Case Reports in Hepatology 2022, pages 1-5.
Crossref
Crossref
Kelsey Klein, Joelle Nelson, Christina Long, Kermit Speeg, Naim Alkhouri & Reed Hall. (2021) Effect of Hepatitis C Viremia on Posttransplant Diabetes Mellitus in Liver Transplant Recipients. Progress in Transplantation 32:1, pages 73-77.
Crossref
Crossref
Gayatri Marathe, Erica E M Moodie, Marie-Josée Brouillette, Joseph Cox, Charlotte Lanièce Delaunay, Curtis Cooper, Mark Hull, John Gill, Sharon Walmsley, Neora Pick & Marina B Klein. (2022) Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada. Antiviral Therapy 27:1, pages 135965352110676.
Crossref
Crossref
William W.L. Wong, Josephine Wong, Karen E. Bremner, Yasmin Saeed, Kate Mason, Arcturus Phoon, Zeny Feng, Jordan J. Feld, Nicholas Mitsakakis, Jeff Powis & Murray Krahn. (2022) Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. Value in Health 25:2, pages 247-256.
Crossref
Crossref
Edwige T. Yelemkoure, Albert T. Yonli, Hermann K. Sombie, Issoufou Tao, Abdou Azaque Zouré, Abdoul Karim Ouattara, Abel P. Sorgho, Arsène W. Zongo, Moctar T.A. Zeba, Isabelle T. Kiendrebeogo, Prosper Bado, Madeleine K. Kabré, Théodora M. Zohoncon, Florencia W. Djigma, Dorcas Obiri-Yeboah & Jacques Simpore. (2022) Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso. Intervirology 65:3, pages 151-159.
Crossref
Crossref
Leran Chen, Ping Ji & Yongsheng Ma. (2022) Machine Learning Model for Hepatitis C Diagnosis Customized to Each Patient. IEEE Access 10, pages 106655-106672.
Crossref
Crossref
Pramod N. Kamalapathy, Avilash Das, Dennis Chen, Jon Raso & Hamid Hassanzadeh. (2022) Treatment of Hepatitis C Virus Prior to Posterior Lumbar Fusion. Clinical Spine Surgery: A Spine Publication Publish Ahead of Print.
Crossref
Crossref
Daniel Valle-Millares, Óscar Brochado-Kith, Alicia Gómez-Sanz, Luz Martín-Carbonero, Pablo Ryan, Ignacio De los Santos, Juan M. Castro, Jesús Troya, Mario Mayoral-Muñoz, Guillermo Cuevas, Paula Martínez-Román, Jesús Sanz-Sanz, María Muñoz-Muñoz, María Á Jiménez-Sousa, Salvador Resino, Verónica Briz & Amanda Fernández-Rodríguez. (2022) HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization. Biomedicine & Pharmacotherapy 145, pages 112405.
Crossref
Crossref
M. Elle Saine, Julia E. Szymczak, Tyler M. Moore, Laura P. Bamford, Frances K. Barg, Kimberly A. Forde, Jason Schnittker, John H. Holmes, Nandita Mitra & Vincent Lo Re. (2021) The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. PLOS ONE 16:10, pages e0258143.
Crossref
Crossref
Jennifer R. Eames & Bau Tran. (2021) Hepatitis C. Physician Assistant Clinics 6:4, pages 555-568.
Crossref
Crossref
Shelley N Facente, Sheena Patel, Jennifer Hecht, Erin Wilson, Willi McFarland, Kimberly Page, Peter Vickerman, Hannah Fraser, Katie Burk & Meghan D Morris. (2021) Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs. Clinical Infectious Diseases 73:6, pages e1290-e1295.
Crossref
Crossref
Ranjan Kumar Barman, Anirban Mukhopadhyay, Ujjwal Maulik & Santasabuj Das. (2021) Identification of Critical Host Targets for HCV Infection: A Systems Biology Approach. Transactions of the Indian National Academy of Engineering 6:3, pages 755-763.
Crossref
Crossref
Taylor A. Vega, Ximena A. Levander, Andrew Seaman, P. Todd Korthuis & Honora Englander. (2021) “Sobriety equals getting rid of hepatitis C”: A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. Journal of Substance Abuse Treatment 127, pages 108337.
Crossref
Crossref
Rosanna Villani, Francesca Di Cosimo, Antonino Davide Romano, Moris Sangineto & Gaetano Serviddio. (2021) Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Scientific Reports 11:1.
Crossref
Crossref
Amina Arif, Naeem Rashid & Muhammad Akhtar. (2021) Removal of N-terminal methionine of human interferon α-2b by co‐producing with Pyrococcus furiosus methionine aminopeptidase in Escherichia coli. Biologia 76:6, pages 1843-1848.
Crossref
Crossref
Donald J. AbrahamDavid A. DeGoey & Philip B. Cox. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
35
.
Eve-Isabelle Pécheur, Fabien Zoulim & Birke Bartosch. 2021. Hepatitis C: Epidemiology, Prevention and Elimination. Hepatitis C: Epidemiology, Prevention and Elimination
1
44
.
William David Green, Erik A. Karlsson & Melinda A. Beck. 2021. Nutrition and Infectious Diseases. Nutrition and Infectious Diseases
133
163
.
Nadia A. Nabulsi, Michelle T. Martin, Lisa K. Sharp, David E. Koren, Robyn Teply, Autumn Zuckerman & Todd A. Lee. (2020) Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy. Frontiers in Pharmacology 11.
Crossref
Crossref
Rachel H. Bianculli, Jonathan D. Mase & Michael D. Schulz. (2020) Antiviral Polymers: Past Approaches and Future Possibilities. Macromolecules 53:21, pages 9158-9186.
Crossref
Crossref
Abdalla Aly, Sarah Ronnebaum, Dipen Patel, Yunes Doleh & Fernando Benavente. (2020) Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepatic Oncology 7:3.
Crossref
Crossref
Sarah C.J. Jorgensen, Christopher L.Y. Tse, Lisa Burry & Linda D. Dresser. (2020) Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40:8, pages 843-856.
Crossref
Crossref
Nahla Fadl & Tamer Z. Salem. (2020)
Hepatitis C genotype 4: A report on resistance‐associated substitutions in
NS3
,
NS5A
,
and
NS5B
genes
. Reviews in Medical Virology 30:4.
Crossref
Crossref
Siamak Salehi, Oliver D. Tavabie, Suman Verma, Mark J. W. McPhail, Farzin Farzaneh, William Bernal, Krish Menon, Kosh Agarwal & Varuna R. Aluvihare. (2020) Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation. Liver Transplantation 26:6, pages 811-822.
Crossref
Crossref
Ed G. Marins, Nicole Krey, Annegret Becker, Sina Melzer & Matthias Hoppler. (2020) Evaluation of the cobas® HCV test for quantifying HCV RNA in dried plasma spots collected using the cobas® Plasma Separation Card. Journal of Virological Methods 278, pages 113820.
Crossref
Crossref
Jeffrey V. Lazarus, Elena Roel & Ahmed M. Elsharkawy. (2020) Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harbor Perspectives in Medicine 10:3, pages a036913.
Crossref
Crossref
Jean-Baptiste Gorin, David F. G. Malone, Benedikt Strunz, Tony Carlsson, Soo Aleman, Niklas K. Björkström, Karolin Falconer & Johan K. Sandberg. (2020) Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. Scientific Reports 10:1.
Crossref
Crossref
Fernanda Bellini Lunardi MICHELS, Ana Cristina de Castro AMARAL, Roberto José de CARVALHO-FILHO, Gustavo de Almeida VIEIRA, Ana Lucia da Silva SOUZA & Maria Lucia Gomes FERRAZ. (2020) HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Arquivos de Gastroenterologia 57:1, pages 45-49.
Crossref
Crossref
Luis Antonio Uribe-Noguez, José Antonio Mata-Marín, Alicia Ocaña-Mondragón, Ericka Nelly Pompa-Mera, Rosa María Ribas-Aparicio, Carla Ileana Arroyo-Anduiza, María Elena Gomez-Torres, Alberto Chaparro-Sánchez, Jesus Gaytán-Martínez & Stefan Mauss. (2020) Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico. Journal of Infection and Chemotherapy 26:2, pages 205-210.
Crossref
Crossref
Chunhong Li, Jing Liang, Huiling Xiang, Haiyan Chen & Jie Tian. (2020) Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine 99:48, pages e23384.
Crossref
Crossref
Leah L. Zullig, Haresh L. Bhatia, Ziad F. Gellad, Mark Eatherly, Rochelle Henderson & Hayden B. Bosworth. (2019) Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. BMC Health Services Research 19:1.
Crossref
Crossref
D. Crowley, R. Murtagh, W. Cullen, J. S. Lambert, T. McHugh & M. C. Van Hout. (2019) Hepatitis C virus infection in Irish drug users and prisoners – a scoping review. BMC Infectious Diseases 19:1.
Crossref
Crossref
Nina Leung, Seth E. Bernacki & Edward J. Bernacki. (2019) A Success Story. Journal of Occupational & Environmental Medicine 61:8, pages e354-e357.
Crossref
Crossref
Raoul Blindenbacher, Bettina Maeschli & Philip Bruggmann. (2019) The Swiss Hepatitis Strategy as a model for facing future health policy challenges. Health Policy 123:7, pages 681-687.
Crossref
Crossref
Kiyotaka Yamazaki, Dendy Macaulay, Yan Song & Yuri Sanchez Gonzalez. (2019) Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infectious Diseases and Therapy 8:2, pages 285-299.
Crossref
Crossref
Dorothy Rosique-Oramas, Moises Martinez-Castillo, Carolina Guzman, José Luis Pérez Hernández, Jacqueline Cordova-Gallardo, Luis Very-Pineda, Fatima Higuera-De La Tijera, Daniel Santana-Vargas, Eduardo Montalvo-Jave, Francisco Sanchez-Avila, Paula Cordero Perez, Linda Muñoz-Espinosa, David Kershenobich & Gabriela Gutiérrez-Reyes. 2019. Liver Cirrhosis - Debates and Current Challenges. Liver Cirrhosis - Debates and Current Challenges.
Lawrence O Gostin, John T Monahan, Jenny Kaldor, Mary DeBartolo, Eric A Friedman, Katie Gottschalk, Susan C Kim, Ala Alwan, Agnes Binagwaho, Gian Luca Burci, Luisa Cabal, Katherine DeLand, Timothy Grant Evans, Eric Goosby, Sara Hossain, Howard Koh, Gorik Ooms, Mirta Roses Periago, Rodrigo Uprimny & Alicia Ely Yamin. (2019) The legal determinants of health: harnessing the power of law for global health and sustainable development. The Lancet 393:10183, pages 1857-1910.
Crossref
Crossref
Lindsay Chalmers. (2019) Hepatitis C: prescribing challenges in the era of new direct-acting antivirals. Journal of Prescribing Practice 1:2, pages 80-85.
Crossref
Crossref
Amber R. Slevin, Mickey J. Hart, Caroline Van Horn, Syed Rahman, Naga Swetha Samji, Aniko Szabo, Lisa Rein, Shannon Werner & Kia Saeian. (2019) Hepatitis C virus direct-acting antiviral nonadherence: Relationship to sustained virologic response and identification of at-risk patients. Journal of the American Pharmacists Association 59:1, pages 51-56.
Crossref
Crossref
James G. Taylor. 2019. HCV: The Journey from Discovery to a Cure. HCV: The Journey from Discovery to a Cure
441
457
.
Rasha Aboshabana, Shereen Shalan, Manal Eid & Nahed El-Enany. (2018) Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti-hepatitis C drug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids. Luminescence 33:8, pages 1333-1345.
Crossref
Crossref
Brian L. Pearlman & Andrew E. Hinds. (2018) Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir. Alimentary Pharmacology & Therapeutics 48:9, pages 914-923.
Crossref
Crossref
Luis Antonio Uribe-Noguez, Alicia Ocaña-Mondragón, José Antonio Mata-Marín, Allison Cázares-Cortázar, Rosa María Ribas-Aparicio, María Elena Gómez-Torres, Jesus Gaytán-Martínez & María de la Luz Martínez-Rodríguez. (2018) Case report: Identification of recombinant HCV genotype 1b–2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir. Journal of Infection and Chemotherapy 24:11, pages 928-931.
Crossref
Crossref
Koji Tsuzaki, Hitoshi Someda, Manabu Inoue, Naoko Tachibana & Toshiaki Hamano. (2018) Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy. Muscle & Nerve 58:5, pages E34-E36.
Crossref
Crossref
Magdalena Harris & Tim Rhodes. (2018) Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. International Journal of Drug Policy 60, pages 24-32.
Crossref
Crossref
Patrick McCabe & Robert J. Wong. (2018) More severe deficits in functional status associated with higher mortality among adults awaiting liver transplantation. Clinical Transplantation 32:9, pages e13346.
Crossref
Crossref
Viktor V. Chirikov, Steven E. Marx, Shivaji R. Manthena, John P. Strezewski & Sammy Saab. (2018) Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016. Advances in Therapy 35:7, pages 1087-1102.
Crossref
Crossref
Luis Antonio Uribe-Noguez, Alicia Ocaña-Mondragón, José Antonio Mata-Marín, María Elena Gómez-Torres, Rosa María Ribas-Aparicio & María de la Luz Martínez-Rodríguez. (2018) Presence of rare hepatitis C virus subtypes, 2j, 2k, and 2r in Mexico City as identified by sequencing. Journal of Medical Virology 90:7, pages 1277-1282.
Crossref
Crossref
Thomas R. Aunins, Katherine A. Marsh, Gitanjali Subramanya, Susan L. Uprichard, Alan S. Perelson & Anushree Chatterjee. (2018) Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms. Journal of Virology 92:11.
Crossref
Crossref
Shelley N. Facente, Katie Burk, Kelly Eagen, Elise S. Mara, Aaron A. Smith & Colleen S. Lynch. (2018) New Treatments Have Changed the Game. Infectious Disease Clinics of North America 32:2, pages 313-322.
Crossref
Crossref
Thomas N. Kakuda, Matthew W. McClure, Christopher Westland, Jennifer Vuong, Marie-Claude Homery, Gwendoline Poizat, Laure Viguerie, Caroline Denot, Alain Patat, Qingling Zhang, James Hui, David Apelian, David B. Smith, Sushmita M. Chanda & John Fry. (2018) Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. Pharmacology Research & Perspectives 6:3, pages e00395.
Crossref
Crossref
Shelley N. Facente, Eduard Grebe, Katie Burk, Meghan D. Morris, Edward L. Murphy, Ali Mirzazadeh, Aaron A. Smith, Melissa A. Sanchez, Jennifer L. Evans, Amy Nishimura & Henry F. Raymond. (2018) Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination. PLOS ONE 13:4, pages e0195575.
Crossref
Crossref
J. Chhatwal, Q. Chen, T. Ayer, E. D. Bethea, F. Kanwal, K. V. Kowdley, X. Wang, M. S. Roberts & S. C. Gordon. (2018) Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Alimentary Pharmacology & Therapeutics 47:7, pages 1023-1031.
Crossref
Crossref
Manish Jha & Madhukar Trivedi. (2018) Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. International Journal of Molecular Sciences 19:1, pages 233.
Crossref
Crossref
Alex M. Dussaq, Abha Soni, Christopher Willey, Seung L. Park & Shuko Harada. (2017) Hepatitis C Virus Genie: A Web 2.0 Interpretation and Analytics Platform for the Versant Hepatitis C Virus Genotype Line Probe Assay Version 2.0. Journal of Pathology Informatics 8:1, pages 41.
Crossref
Crossref